Stay informed

Sign up for resources to help you take charge of your journey with MASH.

Education and helpful information sent straight to your inbox.

    Fill in your information below:

    *Indicates a required field.

    How you’d like to be addressed.
    Where we will send you resources and information.
    Your location helps identify local events or updates in your area.

    Want resources unique to your liver status?

    Select the option that best describes your diagnosis:

    MASH was formerly called NASH (nonalcoholic steatohepatitis).

    By clicking "Submit" you certify that you are 18 years of age or older and are a resident of the United States.

    The information you provide, as applicable based on your responses, will be used by Madrigal Pharmaceuticals, Inc., our affiliates, and our service providers to communicate with you regarding your request. In order to personalize the information you receive, the information you provide during enrollment may be combined with information received from other sources, as described in our Privacy Policy.

    Madrigal respects your personal information. Madrigal or third parties working on their behalf will not sell your personal information. If, in the future, you no longer want to receive health-related materials, you may opt out at any time by clicking here.

    For more information on your privacy rights and how Madrigal Pharmaceuticals, Inc. protects your personal information, please review Madrigal’s Privacy Policy here: https://www.madrigalpharma.com/privacy/.

    Important Safety Information and Indication

    Expand Collapse

    Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

    • have any liver problems other than MASH.
    • have gallbladder problems or have been told you have gallbladder problems, including gallstones.
    • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
    • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or cyclosporine to suppress your immune system, because Rezdiffra is not recommended in patients taking these medicines.
    • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
    • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

    What are the possible side effects of Rezdiffra?

    Rezdiffra may cause serious side effects, including:

    • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness.
    • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

    The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.

    These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1‑800‑905‑0324.

    What is Rezdiffra?

    Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

    This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

    Please see the full Prescribing Information, including Patient Information, for Rezdiffra.

    Important Safety Information and Indication

    Before you take Rezdiffra, tell your healthcare provider about all of your medical conditions, including if you:

    • have any liver problems other than MASH.
    • have gallbladder problems or have been told you have gallbladder problems, including gallstones.
    • are pregnant or plan to become pregnant. It is not known if Rezdiffra will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if Rezdiffra passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Rezdiffra.

    Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    • Rezdiffra and other medicines may affect each other, causing side effects. Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works.
    • Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help lower your triglycerides, or cyclosporine to suppress your immune system, because Rezdiffra is not recommended in patients taking these medicines.
    • Tell your healthcare provider if you are taking medicines such as clopidogrel to thin your blood or statin medicines to help lower your cholesterol.
    • Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

    What are the possible side effects of Rezdiffra?

    Rezdiffra may cause serious side effects, including:

    • liver injury (hepatotoxicity). Stop taking Rezdiffra and call your healthcare provider right away if you develop the following signs or symptoms of hepatotoxicity: tiredness, nausea, vomiting, fever, rash, your skin or the white part of your eyes turns yellow (jaundice), or stomach pain/tenderness.
    • gallbladder problems. Gallbladder problems such as gallstones, or inflammation of the gallbladder, or inflammation of the pancreas from gallstones can occur with MASH and may occur if you take Rezdiffra. Call your healthcare provider right away if you develop any signs or symptoms of these conditions, including nausea, vomiting, fever, or pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen to your back and the pain may happen with or without vomiting.

    The most common side effects of Rezdiffra include diarrhea, nausea, itching, stomach pain, vomiting, dizziness, and constipation.

    These are not all the possible side effects of Rezdiffra. For more information, ask your healthcare provider or pharmacist.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Madrigal Pharmaceuticals, Inc. at 1‑800‑905‑0324.

    What is Rezdiffra?

    Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

    This indication is approved based on improvement of MASH and liver scarring (fibrosis). There are ongoing studies to confirm the clinical benefit of Rezdiffra.

    Please see the full Prescribing Information, including Patient Information, for Rezdiffra.